Reuters logo
BRIEF-Sanofi Genzyme announces positive new six-year data from analysis of lemtrada
April 25, 2017 / 12:26 PM / 5 months ago

BRIEF-Sanofi Genzyme announces positive new six-year data from analysis of lemtrada

April 25 (Reuters) - Sanofi Sa

* Sanofi genzyme - announced positive new six-year investigational data from post-hoc analysis of extension study of lemtrada (alemtuzumab)

* Sanofi genzyme- majority patients treated with lemtrada in phase iii pivotal study care-ms ii did not relapse between their first & second courses of lemtrada

* Sanofi genzyme says 24% of lemtrada-treated patients in care-ms ii relapsed between courses

* Sanofi genzyme -in clinical trials, serious side effects associated with lemtrada included infusion reactions, autoimmune disorders, infections & pneumonitis Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below